Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
المؤلفون المشاركون
Liu, Zhanju
Yu, Lijuan
Yang, Xuehua
Xia, Lu
Zhong, Jie
Ge, Wensong
Wu, Jianxin
Liu, Hongchun
Liu, Fei
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-03-19
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disease (CD) patients.
106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China.
Clinical remission to IFX induction therapy was defined as Crohn’s disease activity index (CDAI) < 150.
Clinical response was assessed by a decrease in CDAI ≥ 70, and the failure as a CDAI was not significantly changed or increased.
Ten weeks after therapy, 61 (57.5%) patients achieved clinical remission, 17 (16.0%) had clinical response, and the remaining 28 (26.4%) were failed.
In remission group, significant changes were observed in CDAI, the Simple Endoscopic Score for Crohn’s Disease (SES-CD), and serum indexes.
Patients with short disease duration (22.2 ± 23.2 months) and luminal lesions showed better effects compared to those with long disease duration (71.0 ± 58.2 months) or stricturing and penetrating lesions.
IFX markedly downregulated Th1/Th17-mediated immune response but promoted IL-25 production in intestinal mucosa from remission group.
No serious adverse events occurred to terminate treatment.
Taken together, our studies demonstrated that IFX is efficacious and safe in inducing clinical remission, promoting mucosal healing, and downregulating Th1/Th17-mediated immune response in short course CD patients with luminal lesions.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yu, Lijuan& Yang, Xuehua& Xia, Lu& Zhong, Jie& Ge, Wensong& Wu, Jianxin…[et al.]. 2015. Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. Mediators of Inflammation،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1072573
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yu, Lijuan…[et al.]. Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. Mediators of Inflammation No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1072573
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yu, Lijuan& Yang, Xuehua& Xia, Lu& Zhong, Jie& Ge, Wensong& Wu, Jianxin…[et al.]. Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. Mediators of Inflammation. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1072573
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1072573
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر